Phase 3 N=450 A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
Seborrheic Keratosis
Primary: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment — 9; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=230 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Phase 3 N=95 Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Central Line-Associated Bloodstream Infection
Primary: Percentage of Therapeutic Failures (Early or Late Failure) in Children and Adolescents With CLABSI Receiving Standard Care Plus Ethanol Lock Therapy (ELT) vs. Standard…
Phase 3 N=208 A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16…
Phase 3 N=487 A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
Seborrheic Keratosis
Primary: Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale — 19; 0 Participants
Phase 3 N=68 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
Chronic Hepatitis C · Hepatitis C Virus · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment — 94.1 percentage of participants
Phase 3 N=101 A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-Dose) — 1.94; 2.86; 2.03; 2.94 units on a scale
Phase 3 N=596 Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
Eczema
Primary: Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24 — 58; 14; 60; 30 Participants — p=<0.001
Phase 3 N=345 Dysport® Adult Lower Limb Spasticity Follow-on Study
Post-stroke Spasticity · Spasticity Post-Traumatic Brain Injury
Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants
Phase 3 N=454 Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
Japanese Encephalitis · Varicella
Primary: Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV — 80.3; 0; 96.2; 15.4 Percentage of participants
Phase 3 N=99 Minocycline and Aspirin in the Treatment of Bipolar Depression
Bipolar Disorder Depression
Primary: Treatment Response — 21; 44; 25; 50 Percentage of Participants
Phase 3 N=943 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.2; 98.2 percentage of participants
Phase 3 N=93 An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)
Osteoarthritis of the Knee
Primary: Percentage of Participants With Drug Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs) — 51.6; 7.5 Percentage of participants
Phase 3 N=992 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo…
Phase 3 N=478 A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
Hepatitis C
Primary: Percentage of Participants Who Experienced Relapse12overall With and Without New HCV Infection — 0.2; 0.2 percentage of participants